Morgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53

Benzinga · 3d ago
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.